Drugs / CD133KDEL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02845414 | Dec 2018 → Jan 2022 | cancer | Masonic Cancer Center, University of Minnesota | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD133KDEL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02845414 ↗ |
| Known as | dCD133KDEL | “This is a single center, phase I dose escalation study designed to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of deimmunized CD133KDEL...” NCT02845414 ↗ |
| Modality | Protein / enzyme biologic | “a ligand-directed, deimmunized pseudomonas toxin against CD133” NCT02845414 ↗ |
| Route | Intravenous | “via a 30-minute intravenous infusion” NCT02845414 ↗ |